AstraZeneca (AZN, Financial), the British pharmaceutical giant, has raised its annual revenue and profit forecasts for the second time in less than four months. This adjustment is driven by strong market demand for its cancer and rare disease medications.
The company, which is listed in London, now anticipates that its 2024 revenue and core earnings per share will increase by more than 15%. This is an improvement from its previous estimate, which projected growth of approximately 15% at constant exchange rates.
